Hong Kong innovative drug concept stocks opened higher, with BeiGene Ltd (NASDAQ: BGNE) up more than 7%, WuXi AppTec Co., Ltd. (SEHK: 02359) up more than 6%, and Akeso Inc. (SEHK: 09926), WuXi Biologics (Cayman) Inc. (SEHK: 02269), and WuXi XDC Cayman Inc. (SEHK: 02268) each up more than 3%.
On the news front, BeiGene disclosed its 2026 third-quarter report, showing that for the first three quarters the company achieved operating revenue of 34.993 billion yuan, up 26.8% year-on-year; net profit attributable to shareholders of 6.055 billion yuan, up 431.8% year-on-year; non-GAAP net profit of 5.568 billion yuan, up 474.4% year-on-year; and basic earnings per share of 4.16 yuan.
In addition, on the morning of November 10, WuXi AppTec issued an announcement stating that on November 9, the company learned that the Department of Defense decided to remove WuXi AppTec from the CMC list under Section 1260H. The Deputy Secretary of Defense determined that it should comply with the court order approving the company's preliminary injunction motion and remove WuXi AppTec from the Department of Defense's updated 1260H list. This decision shields the company from further adverse effects arising from that designation. The company will continue to be committed to serving customers and empowering them to develop life-saving and life-improving medicines for patients.
Citi stated that the U.S. decision to remove WuXi AppTec from the 1260H list is a significant positive for the stock and could boost market sentiment across the entire industry.
Comments